- Home
- MSEX vs SPRY Comparison
MSEX vs SPRY Comparison
Compare MSEX & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSEX
- SPRY
- Stock Information
- Founded
- MSEX 1897
- SPRY 2015
- Country
- MSEX United States
- SPRY United States
- Employees
- MSEX N/A
- SPRY N/A
- Industry
- MSEX Water Supply
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- MSEX Utilities
- SPRY Health Care
- Exchange
- MSEX Nasdaq
- SPRY Nasdaq
- Market Cap
- MSEX 963.9M
- SPRY 1.1B
- IPO Year
- MSEX N/A
- SPRY N/A
- Fundamental
- Price
- MSEX $54.63
- SPRY $8.66
- Analyst Decision
- MSEX Buy
- SPRY Strong Buy
- Analyst Count
- MSEX 3
- SPRY 4
- Target Price
- MSEX $61.67
- SPRY $31.25
- AVG Volume (30 Days)
- MSEX 150.0K
- SPRY 1.7M
- Earning Date
- MSEX 10-31-2025
- SPRY 11-10-2025
- Dividend Yield
- MSEX 2.48%
- SPRY N/A
- EPS Growth
- MSEX 3.71
- SPRY N/A
- EPS
- MSEX 2.39
- SPRY N/A
- Revenue
- MSEX $194,822,000.00
- SPRY $112,339,000.00
- Revenue This Year
- MSEX $4.27
- SPRY N/A
- Revenue Next Year
- MSEX $8.65
- SPRY $193.13
- P/E Ratio
- MSEX $23.01
- SPRY N/A
- Revenue Growth
- MSEX 6.24
- SPRY 22367.80
- 52 Week Low
- MSEX $44.17
- SPRY $8.32
- 52 Week High
- MSEX $70.73
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- MSEX 46.13
- SPRY 34.69
- Support Level
- MSEX $44.94
- SPRY $8.32
- Resistance Level
- MSEX $62.18
- SPRY $9.01
- Average True Range (ATR)
- MSEX 2.74
- SPRY 0.52
- MACD
- MSEX -0.86
- SPRY -0.09
- Stochastic Oscillator
- MSEX 58.78
- SPRY 13.48
About MSEX Middlesex Water Company
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.